Why we love multi-omics analysis
The key challenge to understanding complex biological systems is that they cannot be simply decoded...
BioStrand Omics Analysis Blog:
Multi-Omics
What is a biomarker?
A biomarker, or biological marker, broadly refers to a range of objectively, accurately, and...
What is precision medicine?
In 1999, an innovative collaboration between 10 of the world’s largest pharmaceutical companies,...
The role of NGS in breast cancer diagnosis and treatment
Breast cancer is the most common cancer in women worldwide, accounting for 25% of all female...
A brief retrospective on our second blogiversary
It’s been an eventful two years, to the month, since we launched our omics and analysis blog. Our...
Closing the Gap of Text and the Biosphere with LENSai™ NLP Link
Bridging the gap between raw sequence data, secondary research, experimental data, and the...
AI-powered genomics to advance precision medicine
Sir William Osler, often called the father of modern medicine, was among the first to articulate a ...
AI, NLP and the ROI of drug development
The out-of-pocket R&D costs of developing a single drug, whether successfully launched or not, are...
Accelerating pharma R&D and innovation through technology partnerships
Biopharmas are increasingly turning to alliances & partnerships to drive external innovation....
Functional multiomics and antibody discovery
Genomics is the forerunner of all omics technologies, first introduced in 1987 as the name of a new...
Challenges In Multi-Omics Data Integration
Today, the integrative computational analysis of multi-omics data has become a central tenet of the...